EU Clinical Trial 2017-001747-12

A phase 2, Multicenter, Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups of Pediatric Sickle Cell Disease Patients with Vaso-Occlusive Crisis  Jan 1, 2017

Main objective of the trial: - To confirm and establish appropriate dosing of crizanlizumab in patients ages 6 months to <18 years at the time of study entry (Part A and B) - To evaluate the safety of crizanlizumab in patients ages 6 months to <18 years at the time of study entry (Parts A and B)

Parties

Sponsors